Treatment of irritable bowel syndrome with comorbid anxiety symptoms with mirtazapine

Clinical Neuropharmacology

Volumn 34, Issue 1, 2011, Pages 36-38

  Spiegel, David R ^a   Kolb, Richard ^a  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

Author keywords

anxiety; irritable bowel syndrome; mirtazapine; serotonin receptor type 3

Indexed keywords

LORAZEPAM; MIRTAZAPINE;

AGED; ANALGESIA; ANAMNESIS; ANXIETY DISORDER; CASE REPORT; CLINICAL FEATURE; COLITIS; CONSTIPATION; DEFECATION; DIARRHEA; DISEASE ASSOCIATION; DRUG DOSE REDUCTION; FECES; FEMALE; HUMAN; INTESTINE; IRRITABLE COLON; ISCHEMIC COLITIS; MAJOR DEPRESSION; MENTAL DISEASE; PANIC; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME;

ABDOMINAL PAIN; AGED; ANXIETY DISORDERS; FEMALE; HUMANS; IRRITABLE BOWEL SYNDROME; MIANSERIN; SEROTONIN 5-HT3 RECEPTOR ANTAGONISTS; TREATMENT OUTCOME;

EID: 79551601397     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/WNF.0b013e318209cef2     Document Type: Review

References (16)

1. Yale SH, Musana AK, Kieke A, et al. Applying case definition criteria to irritable bowel syndrome. Clin Med Res 2008;6:9-16.
2. Drossman DA. The functional gastrointestinal disorders and the Rome III process. Gastroenterology 2006;130:1377-1390.
3. Colucci R, Corrado B, Bellini M, et al. The genetics of the serotonin transporter and irritable bowel syndrome. Trends Mol Med 2008;14:295-304.
4. Gershon MD, Tack J. The serotonin signaling system: from basic understanding to drug development for functional GI disorders. Gastroenterology 2007;132:397-414.
5. Yeo A, Boyd P, Lumsden S, et al. Association between a functional polymorphism in the serotonin transporter gene and diarrhea predominant irritable bowel syndrome in women. Gut 2004;53: 1452-1458.
6. Larsson M. Sensory and Secretory Responses to Intestinal Distension; Implicationsfor the Pathophysiology of the Irritable Bowel Syndrome. Goteborg, Sweden: Goteborg University; 2007.
7. Crowell MD. Role of serotonin in the pathophysiology of the irritable bowel syndrome. Br J Pharmacol 2004;141:1285-1293.
8. Christodoulou C, Douzenis A, Moussas G, et al. Effectiveness of mirtazapine in the treatment of postherpetic neuralgia. J Pain Symptom Manage 2010;39(4):e3-e6.
9. Elsenbruch S, Rosenberger C, Enck P, et al. Affective disturbances modulate the neural processing ofvisceral pain stimuli in irritable bowel syndrome: an fMRI study. Gut 2010;59(4):489-495.
10. Trikas P, Vlachonikolis I, Fragkiadakis N, et al. Core mental state in irritable bowel syndrome. Psychosom Med 1999;61:781-788.
11. Lingjoerde O. Lactate-induced panic attacks: possible involvement of serotonin reuptake stimulation. Acta Psychiatr Scand 1985;72:206-208.
12. Den Boer JA, Westenberg HGM. Do panic attacks reflect an abnormality in serotonin receptor subtypes? Hum Psychopharmacology: Clinical and Experimental 1991;6:S25-S30.
13. Camilleri M. Is there a SERT-ain association with IBS? Gut 2004;53:1396-1399.
14. Thomas SG. Irritable bowel syndrome and mirtazapine. Am J Psychiatry 2000;157:1341-1342.
15. Kim SW, Shin IS, Kim JM. Mirtazapine for severe gastroparesis unresponsive to conventional prokinetic treatment. Psychosomatics 2006;47:440M442.
16. Kang EH, Lee IS, Chung SK, et al. Mirtazapine versus venlafaxine for the treatment of somatic symptoms associated with major depressive disorder: a randomized, open-label trial. Psychiatry Research 2009;269:118-123.